The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose Proline, glutamic acid, and leucine-rich protein 1 (PELP1), a novel nuclear receptor (NR) co-regulator, is highly expressed in breast cancer. We investigated its expression in breast cancer subtypes, in comparison with other breast markers as well as cancers from different sites. Its prognostic relevance with different subtypes and other NR expression was also examined in breast cancers. Materials and Methods Immunohistochemical analysis was performed on totally 1,944 cancers from six different organs. Results PELP1 expression rate was the highest in breast cancers (70.5%) among different cancers. Compared to GATA3, mammaglobin and gross cystic disease fluid protein 15, PELP1 was less sensitive than GATA3 for luminal cancers, but was the most sensitive for non-luminal cancers. PELP1 has low expression rate (< 20%) in colorectal cancers, gastric cancers and renal cell carcinomas, but higher in lung cancers (49.1%) and ovarian cancers (42.3%). In breast cancer, PELP1 expression was an independent adverse prognostic factor for nonluminal cancers (disease-free survival [DFS]: hazard ratio [HR], 1.403; p=0.012 and breast cancer specific survival: HR, 1.443; p=0.015). Interestingly, its expression affected the prognostication of androgen receptor (AR). ARposPELP1lo luminal cancer showed the best DFS (log-rank=8.563, p=0.036) while ARnegPELP1hi non-luminal cancers showed the worst DFS (log-rank=9.536, p=0.023). Conclusion PELP1 is a sensitive marker for breast cancer, particularly non-luminal cases. However, its considerable expression in lung and ovarian cancers may limit its utility in differential diagnosis in some scenarios. PELP1 expression was associated with poor outcome in non-luminal cancers and modified the prognostic effects of AR, suggesting the potential significance of NR co-regulator in prognostication.
Abstract
Purpose Proline, glutamic acid, and leucine-rich protein 1 (PELP1), a novel nuclear receptor (NR) co-regulator, is highly expressed in breast cancer. We investigated its expression in breast cancer subtypes, in comparison with other breast markers as well as cancers from different sites. Its prognostic relevance with different subtypes and other NR expression was also examined in breast cancers. Materials and Methods Immunohistochemical analysis was performed on totally 1,944 cancers from six different organs. Results PELP1 expression rate was the highest in breast cancers (70.5%) among different cancers. Compared to GATA3, mammaglobin and gross cystic disease fluid protein 15, PELP1 was less sensitive than GATA3 for luminal cancers, but was the most sensitive for non-luminal cancers. PELP1 has low expression rate (< 20%) in colorectal cancers, gastric cancers and renal cell carcinomas, but higher in lung cancers (49.1%) and ovarian cancers (42.3%). In breast cancer, PELP1 expression was an independent adverse prognostic factor for nonluminal cancers (disease-free survival [DFS]: hazard ratio [HR], 1.403; p=0.012 and breast cancer specific survival: HR, 1.443; p=0.015). Interestingly, its expression affected the prognostication of androgen receptor (AR). ARposPELP1lo luminal cancer showed the best DFS (log-rank=8.563, p=0.036) while ARnegPELP1hi non-luminal cancers showed the worst DFS (log-rank=9.536, p=0.023). Conclusion PELP1 is a sensitive marker for breast cancer, particularly non-luminal cases. However, its considerable expression in lung and ovarian cancers may limit its utility in differential diagnosis in some scenarios. PELP1 expression was associated with poor outcome in non-luminal cancers and modified the prognostic effects of AR, suggesting the potential significance of NR co-regulator in prognostication.
참고문헌 (36)
- Chakravarty D, "PELP1 : a novel therapeutic target for hormonal cancers", IUBMB Life, 62, pp.162~169 (2010)
- Girard BJ, "PELP1 : a review of PELP1 interactions, signaling, and biology", Mol Cell Endocrinol, 382, pp.642~651 (2014)
- Vadlamudi RK, "Functional implications of altered subcellular localization of PELP1 in breast cancer cells", Cancer Res, 65, pp.7724~7732 (2005)
- Mann M, "PELP1 oncogenic functions involve alternative splicing via PRMT6", Mol Oncol, 8, pp.389~400 (2014)
- Rajhans R, "Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1", modulator of the nongenomic actions of the estrogen receptor, 2007, pp.67, 5505~5512
- Cortez V, "PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma", Cancer Res, 74, pp.7395~7405 (2014)
- Brann DW, "PELP1 : a novel estrogen receptor-interacting protein", Mol Cell Endocrinol, 290, pp.2~7 (2008)
- Kumar R, "Extranuclear coactivator signaling confers insensitivity to tamoxifen", Clin Cancer Res, 15, pp.4123~4130 (2009)
- Habashy HO, "The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype", Breast Cancer Res Treat, 120, pp.603~612 (2010)
- Zhang Y, "Prognostic significance of proline, glutamic acid, leucine rich protein 1(PELP1)in triple-negative breast cancer : a retrospective study on 129 cases", BMC Cancer, 15, pp.699~ (2015)
- Dang DN, "Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma : comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma", Hum Pathol, 46, pp.1829~1835 (2015)
- Vadlamudi RK, "Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1", modulator of nongenomic activity of estrogen receptor in human endometrial tumors, 2004, pp.89, 6130~6138
- Aust S, "The prognostic value of estrogen receptor beta and proline-, glutamic acid-and leucine-rich protein 1(PELP1)expression in ovarian cancer", BMC Cancer, 13, pp.115~ (2013)
- Nair SS, "Proline-, glutamic acid-, and leucine-rich protein-1", modulator of nongenomic activity of estrogen receptor enhances androgen receptor functions through LIM-only coactivator, four-and-a-half LIM-only protein 2, 2007, pp.21, 613~624
- Slowikowski BK, "Increased expression of proline-, glutamic acid-and leucinerich protein PELP1 in non-small cell lung cancer", Biomed Pharmacother, 73, pp.97~101 (2015)
- Ning Z, "PELP1suppression inhibits colorectal cancer through c-Src downregulation", Oxid Med Cell Longev, 2014, pp.193523~ (2014)
- Elston CW, "Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer:experience from a large study with long-term follow-up", Histopathology, 19, pp.403~410 (1991)
- Lakhani SR, "WHO classification of tumours of the breast" (2012), IARC Press
- Tsang JY, "PD-L1expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients", Breast Cancer Res Treat, 162, pp.19~30 (2017)
- Tsang JY, "Androgen receptor expression shows distinctive significance in ER positive and negative breast cancers", Ann Surg Oncol, 21, pp.2218~2228 (2014)
- Goldhirsch A, "Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013", Ann Oncol, 24, pp.2206~2223 (2013)
- Nielsen TO, "Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma", Clin Cancer Res, 10, pp.5367~5374 (2004)
- Dimple C, "Role of PELP1", MNAR signaling in ovarian tumorigenesis, 2008, pp.68, 4902~4909
- Yao T, "Identification of genes associated with renal cell carcinoma using gene expression profiling analysis", Oncol Lett, 12, pp.73~78 (2016)
- Grivas PD, "Expression of ERalpha, ERbeta and co-regulator PELP1", MNAR in colorectal cancer : prognostic significance and clinicopathologic correlations, 2009, pp.31, 235~247
- Nishimura R, "Evaluation of factors related to late recurrence later than 10 years after the initial treatmentin primary breast cancer", Oncology, 85, pp.100~110 (2013)
- Tang D, "The expression and clinical significance of the androgen receptor and E-cadherin in triplenegative breast cancer", Med Oncol, 29, pp.526~533 (2012)
- Peters AA, "Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer", Cancer Res, 69, pp.6131~6140 (2009)
- Yang L, "Central role for PELP1 in nonandrogenic activation of the androgen receptor in prostate cancer", Mol Endocrinol, 26, pp.550~561 (2012)
- Nair SS, "Potential role of a novel transcriptional coactivator PELP1 in histone H1 displacement in cancer cells", Cancer Res, 64, pp.6416~6423 (2004)
- Roy S, "Significance of PELP1 in ER-negative breast cancer metastasis", Mol Cancer Res, 10, pp.25~33 (2012)
- Rajhans R, "Modulation of in situ estrogen synthesis by proline-, glutamic acid-, and leucine-rich protein-1 : potential estrogen receptor autocrine signaling loop in breast cancer cells", Mol Endocrinol, 22, pp.649~664 (2008)
- Vadlamudi RK, "Functional and biological properties of the nuclear receptor coregulator PELP1", MNAR, 2007, pp.5, e004~
- Sareddy GR, "PELP1 : Structure, biological function and clinical significance", Gene, 585, pp.128~134 (2016)
- Manavathi B, "Proline-, glutamic acid-, and leucine-rich protein-1 is essential in growth factor regulation of signal transducers and activators of transcription 3 activation", Cancer Res, 65, pp.5571~5577 (2005)
- Truong TH, "Cancer stem cell phenotypes in ER(+)breast cancer models are promoted by PELP1", AIB1 complexes, 2018, pp.16, 707~719